We thank the University of Zurich and the SLS for providing beamtime. Work by the Supuran lab was financed by an EU FP7 grant (Metoxia).
[(Cp-R)M(CO)3] (M=Re or 99mTc) Arylsulfonamide, Arylsulfamide, and Arylsulfamate Conjugates for Selective Targeting of Human Carbonic Anhydrase IX†
Article first published online: 17 FEB 2012
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 51, Issue 14, pages 3354–3357, April 2, 2012
How to Cite
Can, D., Spingler, B., Schmutz, P., Mendes, F., Raposinho, P., Fernandes, C., Carta, F., Innocenti, A., Santos, I., Supuran, C. T. and Alberto, R. (2012), [(Cp-R)M(CO)3] (M=Re or 99mTc) Arylsulfonamide, Arylsulfamide, and Arylsulfamate Conjugates for Selective Targeting of Human Carbonic Anhydrase IX. Angew. Chem. Int. Ed., 51: 3354–3357. doi: 10.1002/anie.201107333
- Issue published online: 27 MAR 2012
- Article first published online: 17 FEB 2012
- Manuscript Revised: 24 JAN 2012
- Manuscript Received: 18 OCT 2011
- bio-organometallic chemistry;
- carbonic anhydrase inhibitors;
Enhanced receptor selectivity: Carbonic anhydrase inhibitors are relevant for both cancer diagnosis and therapy. Combining non-radioactive Re compounds with their radioactive 99mTc homologs enables the use of identical molecules for therapy and imaging (theragnostic). The syntheses and in vitro evaluation of [(Cp-R)M(CO)3] (Cp=cyclopentadienyl, M=Re, 99mTc) with R being a highly potent carbonic-anhydrase-targeting vector is reported (see picture).